Richard Sherva1, Congcong Zhu1, Leah Wetherill2, Howard J Edenberg2,3, Emma Johnson4, Louisa Degenhardt5, Arpana Agrawal4, Nicholas G Martin6, Elliot Nelson4, Henry R Kranzler7, Joel Gelernter8,9, Lindsay A Farrer1,10,11,12,13. 1. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA. 2. Department of Medical and Molecular Genetics and Biochemistry, Indiana University School of Medicine, Indianapolis, IN 46202, USA. 3. Department of Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. 4. Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA. 5. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 6. Queensland Institute of Medical Research Berghofer, Brisbane, QLD 4006, Australia. 7. Perelman School of Medicine, University of Pennsylvania and VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA 19104, USA. 8. Departments of Psychiatry, Genetics and Neuroscience, Yale School of Medicine, New Haven, CT 06511, USA. 9. Department of Psychiatry, VA CT Healthcare Center, West Haven, CT 06516, USA. 10. Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. 11. Department of Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USA. 12. Department of Epidemiology, Boston University School Public Health, Boston, MA 02118, USA. 13. Department of Biostatistics, Boston University School Public Health, Boston, MA 02118, USA.
Abstract
AIM: Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. METHODS: Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. RESULTS: In the discovery sample, three independent regions containing variants associated with time to dependence at P < 5 x 10-8 were identified, one (rs61835088 = 1.03 x 10-8) for cocaine in the combined EA-AA meta-analysis in the gene FAM78B on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, P = 1.37 x 10-8) and 9 (rs7032521, P = 3.30 x 10-8). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, P = 3.71 x 10-9 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, P = 2.57 x 10-8) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. CONCLUSIONS: Although the two GWS variants are not in genes with obvious links to SUD biology and have modest effect sizes, they are statistically robust and show evidence for association in independent samples. These results may point to novel pathways contributing to disease progression and highlight the utility of related phenotypes to better understand the genetics of SUDs.
AIM: Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. METHODS: Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. RESULTS: In the discovery sample, three independent regions containing variants associated with time to dependence at P < 5 x 10-8 were identified, one (rs61835088 = 1.03 x 10-8) for cocaine in the combined EA-AA meta-analysis in the gene FAM78B on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, P = 1.37 x 10-8) and 9 (rs7032521, P = 3.30 x 10-8). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, P = 3.71 x 10-9 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, P = 2.57 x 10-8) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. CONCLUSIONS: Although the two GWS variants are not in genes with obvious links to SUD biology and have modest effect sizes, they are statistically robust and show evidence for association in independent samples. These results may point to novel pathways contributing to disease progression and highlight the utility of related phenotypes to better understand the genetics of SUDs.
Entities:
Keywords:
FAM78B; GWAS; Substance use disorders; cocaine use disorders; genetics; opioid use disorders
Authors: Esther Gramage; Alessia Putelli; Maria J Polanco; Carmen González-Martín; Laura Ezquerra; Luis F Alguacil; Pablo Pérez-Pinera; Thomas F Deuel; Gonzalo Herradón Journal: Addict Biol Date: 2010-10 Impact factor: 4.280
Authors: Amira Pierucci-Lagha; Joel Gelernter; Grace Chan; Albert Arias; Joseph F Cubells; Lindsay Farrer; Henry R Kranzler Journal: Drug Alcohol Depend Date: 2007-06-27 Impact factor: 4.492
Authors: Renato Polimanti; Raymond K Walters; Emma C Johnson; Jeanette N McClintick; Amy E Adkins; Daniel E Adkins; Silviu-Alin Bacanu; Laura J Bierut; Tim B Bigdeli; Sandra Brown; Kathleen K Bucholz; William E Copeland; E Jane Costello; Louisa Degenhardt; Lindsay A Farrer; Tatiana M Foroud; Louis Fox; Alison M Goate; Richard Grucza; Laura M Hack; Dana B Hancock; Sarah M Hartz; Andrew C Heath; John K Hewitt; Christian J Hopfer; Eric O Johnson; Kenneth S Kendler; Henry R Kranzler; Kenneth Krauter; Dongbing Lai; Pamela A F Madden; Nicholas G Martin; Hermine H Maes; Elliot C Nelson; Roseann E Peterson; Bernice Porjesz; Brien P Riley; Nancy Saccone; Michael Stallings; Tamara L Wall; Bradley T Webb; Leah Wetherill; Howard J Edenberg; Arpana Agrawal; Joel Gelernter Journal: Mol Psychiatry Date: 2020-02-26 Impact factor: 15.992
Authors: Sandra Sanchez-Roige; Pierre Fontanillas; Mariela V Jennings; Sevim B Bianchi; Yuye Huang; Alexander S Hatoum; Julia Sealock; Lea K Davis; Sarah L Elson; Abraham A Palmer Journal: Mol Psychiatry Date: 2021-11-02 Impact factor: 13.437